HER2 agonist based on nucleic acid aptamer and application of HER2 agonist
By designing HER2 agonists formed by nucleic acid aptamer linkage, the difficulty of activation caused by the lack of natural ligand of HER2 receptor is solved, and the dimerization and phosphorylation of HER2 receptors are achieved, thereby promoting cell growth, proliferation and healing. Functional, fills the gap in HER2 lacks natural ligands.
Patent Information
- Application Number
- CN202411064447.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-22
AI Technical Summary
The lack of natural ligands of HER2 receptors makes it difficult to achieve homodimeric activation, limiting the performance of cell growth, proliferation and differentiation functions.
A HER2 agonist based on nucleic acid aptamers is designed to form dimer Dimer DNA strands through different numbers of thymine bases, induce the formation of HER2 receptors into dimers and promote phosphorylation activation, and activate downstream signaling pathways.
Without physiological ligand stimulation and HER2 overexpression, high affinity and high specificity bind HER2 receptors to achieve homodimerization activation of HER2, promote cell growth, proliferation, migration and healing, and enhance epithelial barriers Integrity.
Smart Images

Figure BDA0004978956640000061 
Figure BDA0004978956640000071 
Figure BDA0004978956640000072
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a HER2 agonist based on nucleic acid aptamers and applications thereof. Background Art
[0002] HER2 / ErbB2 is a member of the human epidermal growth factor receptor (HER) family. The protein it expresses has tyrosine kinase activity and belongs to the HER receptor tyrosine kinase. Its family members also include EGFRHER1 / ErbB1, HER3 / ErbB3 and HER4 / ErbB4.
[0003] Receptor protein tyrosine kinases (RPTKs) are the largest class of enzyme-linked receptors. They are both receptors and enzymes, and can phosphorylate the tyrosine residues of target proteins by binding to ligands. RPTK has an extracellular ligand binding region, a transmembrane region, and an intracellular catalytic region. When not bound to a signaling molecule, RPTK exists as a monomer and is inactive. When the ligand in the extracellular region binds to a signaling molecule, it leads to the dimerization of the receptor, thereby activating the receptor and inducing phosphorylation of the receptor tyrosine residues. The single phosphotyrosine residue located in the cytoplasmic region of the receptor becomes a highly selective binding site that interacts with specific cytoplasmic signaling molecules. These signaling molecules mediate the cell's response to growth factors through different signal transduction pathways and activate a series of biochemical reactions in the cell.
[0004] HER2 is a receptor tyrosine kinase that binds to the cell membrane surface and participates in signal transduction pathways that lead to cell growth and differentiation. It is usually expressed in epithelial cells of the breast and skin, as well as the gastrointestinal tract, reproductive system, respiratory tract and urinary tract. There are two main signaling pathways activated by HER2: one is the mitogen-activated protein kinase (MAPK) pathway that promotes proliferation, namely the Ras / Raf / MEK / ERK-MAPK pathway, and the other is the phosphatidylinositol 3-kinase-protein kinase B (PI3K-Akt) pathway that promotes cell survival, namely the PI3K / Akt / mTOR pathway. Other pathways include: PLC-γ pathway, JAK-STAT pathway. It has the function of promoting cell survival, proliferation, angiogenesis and differentiation. HER2 is a key component of a complex signaling network and plays a key role in the regulation of tissue development, growth and differentiation. For example, studies have shown that HER2 plays an important role in cardiac and neural development, and HER2 is involved in normal breast growth and development.
[0005] Receptor tyrosine kinases need to form dimers after binding with signal molecules to exert their physiological functions. Although HER2 belongs to receptor tyrosine kinases, it is an orphan receptor. No natural ligand that can directly bind to HER2 has been found so far, and ligands of the epidermal growth factor family cannot directly activate it. However, HER2 can bind to other members of the ErbB family to form heterodimers. For example, under EGF stimulation, HER2 heterodimerizes with EGFR, and under HRG stimulation, it heterodimerizes with HER3, thereby achieving receptor activation.
[0006] In addition, the crystal structure of the HER2 extracellular region adopts an extended configuration, which is similar to the configuration of EGFR in each molecule of the EGFR dimer. Therefore, HER2 has a constitutively active conformation that is independent of the ligand, and when overexpressed, HER2 can achieve homodimerization and activation. However, both activation modes of the HER2 receptor have certain limitations. The activation mode of HER2 forming heterodimers with other family members such as HER1 or HER3 requires corresponding ligand stimulation. When HER2 homodimerizes, HER2 overexpression is required because HER2 lacks natural ligands.
[0007] Nucleic acid aptamers are a class of short single-stranded DNA or RNA oligonucleotides with unique three-dimensional conformations. They are screened from random oligonucleotide libraries based on the SELEX technology and can exert their biological and physiological effects by binding to target molecules with high affinity and high specificity. They have similar or better specificity and affinity than antibodies, can accurately target target proteins, and specifically bind to target proteins. In addition, nucleic acid aptamers have the advantages of simple acquisition, simple synthesis, easy chemical modification, non-denaturation, wide target range, low immunogenicity, and fast cell internalization, and have been widely used in many research fields. Summary of the invention
[0008] The purpose of the first aspect of the present invention is to provide a HER2 agonist.
[0009] The purpose of the second aspect of the present invention is to provide the use of the HER2 agonist of the first aspect of the present invention.
[0010] The third aspect of the present invention aims to provide a product.
[0011] The fourth aspect of the present invention aims to provide a method for promoting HER2 phosphorylation activation, promoting cell proliferation, promoting cell migration and healing, and promoting cell invasion.
[0012] In order to achieve the above object, the technical solution adopted by the present invention is:
[0013] The first aspect of the present invention provides a HER2 agonist, wherein the HER2 agonist is formed by connecting HER2 nucleic acid aptamers to form a dimer DNA chain through different numbers of thymine bases as linkers.
[0014] In some embodiments of the present invention, the nucleotide sequence of the HER2 nucleic acid aptamer is shown in SEQ ID NO:1.
[0015] In some embodiments of the present invention, a certain position on the nucleotide sequence of the HER2 nucleic acid aptamer is phosphorylated, oxygen-methylated, methylated, aminated, sulfhydrylated, fluorinated or isotopized.
[0016] In some embodiments of the present invention, the two ends of the HER2 nucleic acid aptamer are optionally modified with amino, carboxyl, sulfhydryl, fluorescent molecule, biotin, cholesterol or polyethylene glycol groups, such as TAMRA modification at the 5' end, and the modified nucleic acid aptamer molecule can bind to HER2 polypeptide and HER2 positive cells.
[0017] The above nucleotide sequences, whether partially substituted or modified, have substantially the same or similar molecular structures, physicochemical properties and functions as the original nucleic acid aptamers and can be used to specifically bind to the HER2 receptor.
[0018] HER2 nucleic acid aptamers are constructed into DNA agonists through linkers, which effectively promote the formation of HER2 receptor dimers and phosphorylation activation.
[0019] In some embodiments of the present invention, the number of the thymine bases is 0-20.
[0020] In some embodiments of the present invention, the sequence of the HER2 agonist is shown in any one of SEQ ID NO: 2 to SEQ ID NO: 5.
[0021] In some preferred embodiments of the present invention, the sequence of the HER2 agonist is shown in SEQ ID NO:2.
[0022] In some embodiments of the present invention, the HER2 agonist can also be a dimer DNA chain formed by connecting HER2 nucleic acid aptamers in the prior art through different numbers of thymine bases as linkers, such as the aptamer 2-2 aptamer in "Aptamer to ErbB-2 / HER2 enhances degradation of the target and inhibits tumorigenic growth", the SH-1194-35 aptamer in "PET imaging of HER2 expression with an 18F-fluoride labeled aptamer", and the HeA2_3 aptamer in "An aptamer-based colorimetric lateral flow assay for the detection of human epidermal growth factor receptor 2 (HER2)".
[0023] In some embodiments of the present invention, the preparation method of the HER2 agonist comprises the following steps: after designing the nucleotide sequence of the DNA agonist, entrusting a company (such as Shanghai Sangon Biotechnology Co., Ltd.) to synthesize the DNA chain, centrifuging the synthesized DNA chain dry powder, dissolving the DNA dry powder with ultrapure water and vortexing, preparing a 10 μM concentration solution, and storing it in a 4°C refrigerator.
[0024] The third aspect of the present invention provides the use of the HER2 agonist of the third aspect of the present invention in at least one of (1) to (10):
[0025] (1) Inducing HER2 receptor dimerization;
[0026] (2) preparing products that induce HER2 receptor dimerization;
[0027] (3) Preparation of products that regulate the PI3K / Akt / mTOR signaling pathway;
[0028] (4) Preparation of products that regulate Ras / Raf / MEK / ERK-MAPK signaling pathways;
[0029] (5) Promote HER2 receptor phosphorylation;
[0030] (6) preparing products that promote HER2 receptor phosphorylation;
[0031] (7) Promote cell growth, proliferation, and migration;
[0032] (8) Preparation of products that promote cell growth, proliferation, and migration;
[0033] (9) Preparation of products for tissue repair, wound healing, and enhancement of epithelial barrier integrity;
[0034] (10) Construct a cell model.
[0035] In some embodiments of the present invention, the cells described in (7) and (8) are cells with low HER2 expression, such as at least one of cochlear supporting cells, cardiomyocytes, bronchial epithelial cells, oocytes, and neural Schwann cells.
[0036] In some embodiments of the present invention, the cell model in (10) includes at least one of a HER2 receptor DNA agonist HER2 phosphorylation activation model, a cell proliferation model, a cell migration and healing model, and a cell invasion model.
[0037] The fourth aspect of the present invention provides a product comprising the HER2 agonist of the first aspect of the present invention.
[0038] In some embodiments of the present invention, the product includes a reagent, a kit and / or a drug.
[0039] In some embodiments of the present invention, the product has at least one of the following functions:
[0040] 1) Induce HER2 receptor dimerization;
[0041] 2) Regulate the PI3K / Akt / mTOR signaling pathway;
[0042] 3) Regulate Ras / Raf / MEK / ERK-MAPK signaling pathway;
[0043] 4) Promote HER2 receptor phosphorylation;
[0044] 5) Promote cell growth, proliferation and migration;
[0045] 6) Promote tissue repair, wound healing, and enhance epithelial barrier integrity.
[0046] The fifth aspect of the present invention provides a method for promoting HER2 phosphorylation activation, promoting cell proliferation, promoting cell migration and healing, and promoting cell invasion, comprising the step of treating cells with the HER2 agonist of the first aspect of the present invention.
[0047] In some embodiments of the present invention, during the treatment process, 10 to 500 nM of a HER2 agonist is used to treat the cells.
[0048] The beneficial effects of the present invention are:
[0049] The present invention is based on HER2 nucleic acid aptamers and designs a DNA-based HER2 agonist, which can induce HER2 receptor dimerization, promote HER2 receptor phosphorylation, and activate its downstream signaling pathway without the need for physiological ligand stimulation and HER2 overexpression, thereby exerting the physiological functions of HER2 in promoting cell survival, proliferation, angiogenesis, differentiation, etc.
[0050] The HER2 agonist based on nucleic acid aptamers of the present invention can bind to the HER2 receptor with high affinity and high specificity, has the advantages of good stability, easy synthesis, easy modification, short sequence length and low cost, and is conducive to large-scale industrial production and application.
[0051] HER2 is of great significance to normal cell growth, proliferation and differentiation, but since HER2 is a receptor tyrosine kinase lacking a natural ligand, it is difficult to achieve homodimerization activation of HER2 when HER2 is not overexpressed. The present invention uses nucleic acid aptamers with the advantages of simple acquisition, simple synthesis, easy chemical modification, non-denaturation, and low immunogenicity to design HER2 agonists. The developed new DNA agonist for HER2 can specifically and selectively bind to the HER2 receptor, and can achieve homodimerization activation of HER2 without the need for a natural ligand, and can effectively induce dimerization of HER2 receptors on the cell membrane, phosphorylate them, and then activate downstream signaling pathways. It can promote cell growth, proliferation and wound healing, and can also increase the migration and invasion ability of cells. DNA agonists combine the advantages of nucleic acid aptamers and make up for the lack of natural ligands for HER2. As a new type of HER2 ligand that is easy to synthesize artificially, they are of great significance for promoting HER2 to play its physiological functions in cell survival, proliferation, angiogenesis and differentiation, achieving cell therapy in terms of cell growth, tissue repair, wound healing and enhancing epithelial barrier integrity, as well as the application of nucleic acid aptamers in biomedicine, regenerative medicine and other fields. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 Characterization of the performance of DNA aptamer binding to the target HER2 receptor; wherein, a is the laser confocal imaging of the A549 and 4T1 cell membrane surface; b is the flow cytometry of A549 cells, DU45 cells, and HER2-negative cells 4T1 and MCF-7; c is the concentration gradient diagram of different cell flow cytometry, Scale bars = 20 μm.
[0053] Figure 2Comparison of the phosphorylation activation effects of different DNA agonists on the HER2 receptor; a is the immunoblot representation of the phosphorylation activation of the HER2 receptor induced by 6 DNA agonists; b is the immunoblot representation of the phosphorylation activation of the HER2 receptor induced by 4 DNA agonists.
[0054] Figure 3 The figure is a characterization of the phosphorylation activation of HER2 receptor by the HER2 agonist Dimer based on nucleic acid aptamer; wherein, a is a schematic diagram of the nucleic acid aptamer Dimer inducing homodimerization activation of HER2 receptor; b is the immunoblotting characterization of the phosphorylation of HER2 by the nucleic acid aptamer Dimer in A549 cells; c~d are the immunoblotting characterizations of the phosphorylation of HER2 by different concentration gradients of the nucleic acid aptamer Dimer in DU145 cells.
[0055] Figure 4 The HER2 agonist Dimer based on nucleic acid aptamer activates the downstream signaling pathway of HER2 receptor; wherein, a is the immunoblot characterization of the phosphorylation activation of Erk in A549 cells by nucleic acid aptamer Dimer; b is the immunoblot characterization of the phosphorylation activation of Akt in A549 cells by nucleic acid aptamer Dimer; c is the immunoblot characterization of the phosphorylation of Erk in DU145 cells by Dimer; d is the immunoblot characterization of the phosphorylation of Akt in DU145 cells by Dimer.
[0056] Figure 5 Dimer, a HER2 agonist based on nucleic acid aptamer, promotes cell growth and proliferation; a is the CCK-8 experiment of DU145 cells, which significantly promoted cell growth at 24h (left) and 48h (right); b is the CCK-8 experiment of A549 cells; in the figure, * represents p<0.05, ** represents p<0.01, *** represents p<0.001, **** represents p<0.0001, n=6.
[0057] Figure 6 The HER2 agonist Dimer based on nucleic acid aptamer promotes cell migration and invasion; wherein, a is a schematic diagram of the cell invasion experiment; b is a cell migration experiment of DU145 cells, Scale bars = 1000 μm; c is a quantitative analysis diagram of the cell migration experiment; d is a cell invasion experiment of DU145 cells, Scale bars = 100 μm; in the figure, * represents p < 0.05, ** represents p < 0.01, n = 3. DETAILED DESCRIPTION
[0058] The present invention is further described in detail below through specific examples.
[0059] It should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0060] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0061] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0062] Experimental materials: The experimental materials used are shown in Table 1, and the DNA sequence information is shown in Table 2.
[0063] Table 1 Experimental materials
[0064]
[0065]
[0066] Table 2 DNA sequence information
[0067]
[0068] HER2 agonist design scheme: Based on different HER2-specific aptamers, by adding different numbers of thymine bases (T bases) as linkers, two identical aptamer chains are connected into a dimeric dimer DNA chain to bind to two HER2 receptors, inducing the dimerization and activation of the two HER2 receptors.
[0069] Experimental methods:
[0070] 1. Confocal Microscopy Experiment
[0071] The cells were seeded on a confocal dish and cultured in a carbon dioxide incubator. When the cells grew to 30% to 50%, the culture medium was discarded and the cells were washed three times with PBS. 5'-end TAMRA-labeled Apt-HER2 chain (200 nM) was added to human non-small cell lung cancer cells (A549) and mouse breast cancer cells (4T1), respectively, and the cells were incubated at 37°C for 45 min, washed three times with PBS, and images were taken using a Zeiss laser confocal microscope with a 40x oil objective.
[0072] 2. Flow cytometry analysis
[0073] After culturing the cells in a carbon dioxide incubator for 24 h, the cells were washed twice with PBS, digested with enzyme-free digestion solution for 15 min, centrifuged at 4°C for 3 min (speed 600 rcf), and the supernatant was discarded. The binding buffer (containing 5 mM MgCl) containing 5'-end TAMRA-labeled Apt-HER2 (Table 2) (0 nM, 20 nM, 50 nM, 100 nM, 200 nM, 500 nM) was used. 2 The cells were treated with PBS buffer (1% PBS) and incubated at 37°C for 45 min. After incubation, the supernatant was discarded, the cells were washed twice with PBS, and the cells were resuspended in serum-free basal medium. The fluorescence data of the cells were collected by flow cytometry (Beckman Coulter CytoFLEX). Finally, the experimental results of flow cytometry were analyzed by FlowJo v10 software.
[0074] 3. Protein Immunoblotting
[0075] A549 cells and human prostate cancer cells (DU145) were revived and subcultured for more than three generations, then inoculated in 35 mm cell culture dishes. When the cells grew to 80%, they were starved using a culture medium containing 0.2% serum. After starvation for 24 h, the culture medium was replaced with a solution containing EGF (epidermal growth factor) or a DNA strand solution of different concentrations (using a solution containing 5 mM MgCl 2 The cells were incubated in a 37°C CO2 incubator for 45 min, then taken out and placed on ice to terminate the reaction, and washed 3 times with PBS. The cells were then lysed using RIPA lysis buffer containing 1% phosphatase inhibitors and protease inhibitors, and collected in a 1.5 mL centrifuge tube with a cell scraper, centrifuged at 12000 rcf for 10 min at 4°C, and the supernatant was collected and stored in a -20°C refrigerator for later use.
[0076] After the cell lysate was mixed with the protein loading buffer, it was denatured at 100°C for 5 minutes and then centrifuged, and electrophoresis was performed using 8% SDS-PAGE. After the electrophoresis, the sample was transferred to a polyvinylidene chloride membrane (PVDF) by wet transfer, blocked with 5% BSA blocking solution at room temperature, and then the PVDF membrane was incubated with the corresponding primary antibody in a 4°C refrigerator overnight, washed 3 times with TBST solution, and then incubated with the corresponding secondary antibody at room temperature for 1 hour and washed 3 times. Finally, the experimental results of Western Blot were observed and collected by a multifunctional imaging system.
[0077] 4. Cell Proliferation Assay
[0078] A549 cells and DU145 cells were revived and passed for more than three generations, inoculated in 96-well plates, about 5,000 cells per well, and cultured for 24 hours. After the cells adhered to the wall, 100 μL of DNA chain solution prepared with starvation medium was added to each well, and cultured at 37°C for 24 hours and 48 hours, respectively. 10% CCK-8 reagent was added to the cell system, and after incubation at 37°C in the dark for 30 minutes, the OD value at 450nm was measured with an enzyme marker. The cell survival rate was calculated using the following formula:
[0079] Cell viability (%) = [A(drug added) - A(blank)] / [A(0 drug added) - A(blank)] × 100
[0080] A (drug addition): OD value of the wells with cells, CCK-8 solution, and drug solution;
[0081] A (0 drug addition): OD value of the well with cells and CCK-8 solution but no drug solution;
[0082] A (blank): OD value of the well with CCK-8 solution but no cells.
[0083] 5. Cell scratch healing assay
[0084] DU145 cells were seeded in 96-well plates for 24 hours and then starved for 24 hours using 1640 medium containing 0.2% serum. The fused cell monolayer was evenly scraped with a sterile 10 μL pipette tip, the medium was discarded, and the cells were washed 3 times to remove floating cells. The width of the wound was measured and recorded at 0 hours, after which the cells were incubated with EGF and functional nucleic acid dimer (200 nM) prepared in starvation medium. The wound healing was observed at 0 hours, 6 hours, 12 hours, and 24 hours using a Cytation 5 instrument.
[0085] 6. Cell invasion assay process ( Figure 6 a)
[0086] Dilute the matrix gel with serum-free medium precooled at 4°C at a ratio of 1:8, mix well and spread on the bottom of the upper chamber of the Transwell chamber. After the matrix gel gradually solidifies into a gel, the liquid in the upper chamber is discarded. Take out the previously starved DU145 cells from the incubator, discard the culture medium, wash them three times with PBS and digest the cells, then resuspend the cells in serum-free medium and adjust the cell density to 5×10 4. Take 200 μL of cell suspension and add it to the Transwell chamber, and add 600 μL of complete culture medium containing chemokine EGF or Dimer-HER2 to the lower chamber. Place the 24-well plate in a cell culture incubator at 37°C and 5% for 24 hours. Remove the chamber with tweezers and discard the liquid in the upper chamber. Wash it with PBS solution three times, wipe the cells in the migration chamber that have not infiltrated the basement membrane with a cotton swab, fix the cells with 4% paraformaldehyde for 15 minutes, stain them with 0.1% crystal violet for 15 minutes, and finally wash them with PBS three times. Use a microscope to randomly select different fields of view to take pictures.
[0087] Experimental results:
[0088] 1. Nucleic acid aptamers can selectively bind to HER2 receptors
[0089] The present invention investigated the binding of the selected nucleic acid aptamer chain on the surface of the cell membrane of human non-small cell lung cancer A549 through confocal microscopy experiments. From the laser confocal fluorescence image, it can be seen that Apt-HER2 labeled with TAMRA at the 5' end binds to the cell membrane surface of A549 and emits red fluorescence. When HER2-negative 4T1 cells are used as a control, no obvious fluorescence is observed on its surface ( Figure 1 a). This indicates that the nucleic acid aptamer used can selectively and effectively bind to the HER2 receptor on the cell membrane surface. At the same time, the results of flow cytometry further confirmed that the nucleic acid aptamer chain can bind well to human non-small cell lung cancer A549 cells and human prostate cancer cells DU145 that express HER2 receptors. For HER2-negative mouse breast cancer cells 4T1 and human breast cancer cells MCF-7, the aptamer chain labeled with TAMRA at the 5' end binds weakly ( Figure 1 At the same time, the concentration gradient experiment confirmed that the binding of HER2 receptor to aptamer chain was concentration-dependent ( Figure 1 (c).
[0090] 2. DNA agonist dimer targeting HER2 based on nucleic acid aptamers can activate HER2-related signaling pathways
[0091] After verifying that the aptamer can effectively bind to the HER2 receptor, the present invention constructs a DNA agonist based on the aptamer to bind to the two anchored HER2 receptors to induce dimerization and phosphorylation ( Figure 3 First, the activation effects of HER2 agonists based on different aptamer chains on HER2 were compared by immunoblotting experiments. It was found that the DNA agonist Dimer-HER2 constructed based on Apt-HER2 had the most significant effect on the phosphorylation activation of HER2 receptors compared with other DNA agonists ( Figure 2Next, the phosphorylation of HER2 induced by DNA agonist Dimer-HER2 in A549 cells was further characterized. The results showed that DNA agonist Dimer-HER2 can activate HER2 receptors on the surface of A549 cells to varying degrees with increasing concentration. Figure 3 As shown in Figure b, as the concentration of the dimer DNA agonist increases, the phosphorylation of HER2 gradually increases. When the concentration of the DNA agonist reaches 500nM, the phosphorylation level decreases, probably because HER2 activation reaches a critical point, triggering other signaling mechanisms. Similarly, using human prostate cancer cell DU145 for immunoblotting experiments, it was observed that the DNA agonist Dimer-HER2 we constructed can also activate the HER2 receptor on the surface of DU145 and induce its phosphorylation ( Figure 3 (c~d).
[0092] 3. DNA agonist Dimer regulates HER2 downstream signaling pathway transduction
[0093] After dimer DNA agonists induce HER2 phosphorylation, downstream signal transduction is triggered. Erk and Akt are two important protein kinases in the HER2 signaling pathway. Their activation can induce cell proliferation, migration and other behaviors. In order to study the downstream signal transduction after dimer DNA agonists activate HER2, the present invention investigates the phosphorylation activation of Erk and Akt in A549 cells and DU145 cells induced by DNA agonists. Through immunoblotting experiments, it was confirmed that under the stimulation of DNA agonists, the activation of Erk and Akt in A549 cells was successfully induced ( Figure 4 The ability of DNA agonists to promote phosphorylation of Erk and Akt protein kinases in the HER2 downstream signaling pathway was also confirmed in DU145 cells ( Figure 4 (c~d).
[0094] 4. Regulation of cell behavior by the HER2 pathway regulated by the DNA agonist Dimer
[0095] In the HER2-related signaling pathway, activation of Erk protein kinase promotes cell proliferation, while activation of Akt causes rearrangement of cytoskeleton protein actin, improving the movement and migration ability of cells. In order to verify the regulation of cell behavior by DNA agonists, the present invention uses A549 and DU145 cells to verify the effect of DNA agonists on cell proliferation through CCK-8 experiments. Figure 5 As shown in Figure a, compared with the control group, DNA agonist can significantly promote the proliferation of DU145 cells at 24h and 48h. Similarly, DNA agonist also significantly promotes the growth of A549 cells at 48h ( Figure 5 (b)
[0096] Through the wound healing test, the results showed that compared with the blank control group, the DU145 cells treated with DNA agonists showed a good effect of promoting wound healing within 24 hours ( Figure 6 In order to further investigate the ability of DNA agonists to promote cell migration and invasion, we used DU145 cells to conduct a cell invasion experiment and verified that DNA agonists can promote cell invasion ( Figure 6 (d) The above results successfully proved that after DNA agonists induced HER2 activation, it triggered the phosphorylation activation of Erk and Akt in its downstream signaling pathway, and successfully increased cell proliferation and motility, thereby achieving the regulation of cell behavior.
[0097] The HER2 pathway is a key component of the complex signaling network of cells. Many studies have shown that the activation of the HER2 pathway contributes to the growth of cochlear supporting cells (ZHANG J, WANG Q, ABDUL-AZIZ D, et al. ERBB2 signaling drives supporting cell proliferation in vitro and apparent supernumerary hair cell formation in vivo in the neonatal mouse cochlea [J]. European Journal of Neuroscience, 2018, 48 (10): 3299-316), and has the potential to promote the regeneration of human auditory cells. At the same time, HER2 activation can also promote the regeneration of cardiomyocytes (D'UVA G, AHARONOV A, LAURIOLA M, et al. ERBB2 triggersmammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation [J]. Nature Cell Biology, 2015, 17 (5): 627-38), and it also plays an important role in the growth, proliferation and differentiation of neural Schwann cells (GARRATT AN, VOICULESCU O, TOPILKO P, et al. A dual roleof erbB2 in myelination and in expansion of the Schwann cell precursor pool[J].Journal of Cell Biology,2000,148(5):1035-46,GOODEARL A,VIEHOVER A,VARTANIAN T.Neuregulin-induced association of SOS Ras exchange protein withHER2(erhB2) / HER3(erbB3)receptor complexes in Schwann cells through a specificGrb2-HER2(erb62)interaction[J]. Developmental Neuroscience, 2001, 23(1):25-30.), HER2 pathway activation can also enhance the integrity of the bronchial epithelial barrier (GON Y, MATSUMOTO K, TERAKADO M, et al. Heregulin activation of ErbB2 / ErbB3 signaling potentiates the integrity of airway epithelial barrier [J]. Experimental Cell Research, 2011, 317 (13): 1947-53), and the lack of HER2 is lethal to newborn embryos. Studies have shown that homozygous knockout mice lacking HER2 die in mid-gestation (embryonic day 10.5) and have severe heart defects, including cardiac enlargement with thinning of ventricular muscle, loss of trabeculae and reduction of atrioventricular cushions, leading to poor blood circulation and arrhythmia (LEE KF, SIMON H, CHEN H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development [J]. Nature (London), 1995, 378 (6555): 394-8., NEGRO A, BRAR BK, LEE KF. Essential roles of Her2 / erbB2 in cardiac development and function [M] / / MEANSA R. Recent Progress in Hormone Research, Vol 59: Cardiovascular Endocrinology & Obesity. 2004: 1-12). The above experiments successfully verified that the HER2 agonist constructed based on the aptamer of the present invention can effectively activate the HER2 signaling pathway in cells and promote HER2 to play its physiological functions such as promoting cell growth, proliferation, migration, and differentiation, which is of great significance for the treatment of diseases with HER2 deficiency or decreased expression. .
[0098] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. A HER2 agonist, wherein the HER2 agonist is formed by connecting HER2 nucleic acid aptamers to form a dimerized Dimer DNA chain through different numbers of thymine bases as linkers.
2. The HER2 agonist according to claim 1, characterized in that The nucleotide sequence of the HER2 nucleic acid aptamer is shown in SEQ ID NO:
1.
3. The HER2 agonist according to claim 1, characterized in that A certain position on the nucleotide sequence of the HER2 nucleic acid aptamer is phosphorylated, oxygenated, methylated, aminated, sulfhydrylated, fluorinated or isotopized; and / or, both ends of the nucleic acid aptamer are optionally modified with amino, carboxyl, sulfhydryl, fluorescent molecule, biotin, cholesterol or polyethylene glycol groups.
4. The HER2 agonist according to any one of claims 1 to 3, characterized in that The number of the thymine bases is 0-20.
5. The HER2 agonist according to any one of claims 1 to 3, characterized in that The sequence of the HER2 agonist is shown in any one of SEQ ID NO: 2 to SEQ ID NO:
5.
6. Use of the HER2 agonist according to any one of claims 1 to 5 in at least one of (1) to (10): (1) Inducing HER2 receptor dimerization; (2) preparing products that induce HER2 receptor dimerization; (3) Preparation of products that regulate the PI3K / Akt / mTOR signaling pathway; (4) Preparation of products that regulate Ras / Raf / MEK / ERK-MAPK signaling pathways; (5) Promote HER2 receptor phosphorylation; (6) preparing products that promote HER2 receptor phosphorylation; (7) Promote cell growth, proliferation, and migration; (8) Preparation of products that promote cell growth, proliferation, and migration; (9) Prepare products that promote tissue repair, wound healing, and enhance epithelial barrier integrity; (10) Construct a cell model.
7. The use according to claim 6, characterized in that: The cells described in (7) and (8) are cells with low HER2 expression.
8. The use according to claim 6, characterized in that: (10) The cell model includes at least one of a HER2 receptor DNA agonist HER2 phosphorylation activation model, a cell proliferation model, a cell migration and healing model, and a cell invasion model.
9. A product comprising the HER2 agonist according to any one of claims 1 to 5.
10. A method for promoting HER2 phosphorylation activation, cell proliferation, cell migration and healing, and cell invasion, comprising the step of treating cells with the HER2 agonist according to any one of claims 1 to 5.
Citation Information
Patent Citations
Membrane protein analysis method based on DNA molecule cascade signal amplification
CN106011235A
Method for detecting concentration of human epidermal growth factor receptor-2 (HER-2)
CN106226374A
Aptamer drug conjugate as well as preparation method and application thereof
CN112007169A
HER2-targeted DNA coupling chemotherapeutic drug
CN117717619A
Dual-specific aptamer triggering cell-mediated cytotoxicity to LYSE her2-positive cancer cells
WO2022144815A1
